Cargando…
Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer
BACKGROUND: CpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor suppressor genes, leading to their transcriptional silencing and loss of function. While the prevalence of CRC differs across geographica...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796359/ https://www.ncbi.nlm.nih.gov/pubmed/31623592 http://dx.doi.org/10.1186/s12885-019-6144-9 |
_version_ | 1783459568011968512 |
---|---|
author | Advani, Shailesh Mahesh Advani, Pragati Shailesh Brown, Derek W. DeSantis, Stacia M. Korphaisarn, Krittiya VonVille, Helena M. Bressler, Jan Lopez, David S. Davis, Jennifer S. Daniel, Carrie R. Sarshekeh, Amir Mehrvarz Braithwaite, Dejana Swartz, Michael D. Kopetz, Scott |
author_facet | Advani, Shailesh Mahesh Advani, Pragati Shailesh Brown, Derek W. DeSantis, Stacia M. Korphaisarn, Krittiya VonVille, Helena M. Bressler, Jan Lopez, David S. Davis, Jennifer S. Daniel, Carrie R. Sarshekeh, Amir Mehrvarz Braithwaite, Dejana Swartz, Michael D. Kopetz, Scott |
author_sort | Advani, Shailesh Mahesh |
collection | PubMed |
description | BACKGROUND: CpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor suppressor genes, leading to their transcriptional silencing and loss of function. While the prevalence of CRC differs across geographical regions, no studies have compared prevalence of CIMP-High phenotype across regions. The purpose of this project was to compare the prevalence of CIMP across geographical regions after adjusting for variations in methodologies to measure CIMP in a meta-analysis. METHODS: We searched PubMed, Medline, and Embase for articles focusing on CIMP published from 2000 to 2018. Two reviewers independently identified 111 articles to be included in final meta-analysis. We classified methods used to quantify CIMP into 4 categories: a) Classical (MINT marker) Panel group b) Weisenberg-Ogino (W-O) group c) Human Methylation Arrays group and d) Miscellaneous group. We compared the prevalence of CIMP across geographical regions after correcting for methodological variations using meta-regression techniques. RESULTS: The pooled prevalence of CIMP-High across all studies was 22% (95% confidence interval:21–24%; I(2) = 94.75%). Pooled prevalence of CIMP-H across Asia, Australia, Europe, North America and South America was 22, 21, 21, 27 and 25%, respectively. Meta-regression analysis identified no significant differences in the prevalence of CIMP-H across geographical regions after correction for methodological variations. In exploratory analysis, we observed variations in CIMP-H prevalence across countries. CONCLUSION: Although no differences were found for CIMP-H prevalence across countries, further studies are needed to compare the influence of demographic, lifestyle and environmental factors in relation to the prevalence of CIMP across geographical regions. |
format | Online Article Text |
id | pubmed-6796359 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67963592019-10-21 Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer Advani, Shailesh Mahesh Advani, Pragati Shailesh Brown, Derek W. DeSantis, Stacia M. Korphaisarn, Krittiya VonVille, Helena M. Bressler, Jan Lopez, David S. Davis, Jennifer S. Daniel, Carrie R. Sarshekeh, Amir Mehrvarz Braithwaite, Dejana Swartz, Michael D. Kopetz, Scott BMC Cancer Research Article BACKGROUND: CpG Island Methylator Phenotype (CIMP) is an epigenetic phenotype in CRC characterized by hypermethylation of CpG islands in promoter regions of tumor suppressor genes, leading to their transcriptional silencing and loss of function. While the prevalence of CRC differs across geographical regions, no studies have compared prevalence of CIMP-High phenotype across regions. The purpose of this project was to compare the prevalence of CIMP across geographical regions after adjusting for variations in methodologies to measure CIMP in a meta-analysis. METHODS: We searched PubMed, Medline, and Embase for articles focusing on CIMP published from 2000 to 2018. Two reviewers independently identified 111 articles to be included in final meta-analysis. We classified methods used to quantify CIMP into 4 categories: a) Classical (MINT marker) Panel group b) Weisenberg-Ogino (W-O) group c) Human Methylation Arrays group and d) Miscellaneous group. We compared the prevalence of CIMP across geographical regions after correcting for methodological variations using meta-regression techniques. RESULTS: The pooled prevalence of CIMP-High across all studies was 22% (95% confidence interval:21–24%; I(2) = 94.75%). Pooled prevalence of CIMP-H across Asia, Australia, Europe, North America and South America was 22, 21, 21, 27 and 25%, respectively. Meta-regression analysis identified no significant differences in the prevalence of CIMP-H across geographical regions after correction for methodological variations. In exploratory analysis, we observed variations in CIMP-H prevalence across countries. CONCLUSION: Although no differences were found for CIMP-H prevalence across countries, further studies are needed to compare the influence of demographic, lifestyle and environmental factors in relation to the prevalence of CIMP across geographical regions. BioMed Central 2019-10-17 /pmc/articles/PMC6796359/ /pubmed/31623592 http://dx.doi.org/10.1186/s12885-019-6144-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Advani, Shailesh Mahesh Advani, Pragati Shailesh Brown, Derek W. DeSantis, Stacia M. Korphaisarn, Krittiya VonVille, Helena M. Bressler, Jan Lopez, David S. Davis, Jennifer S. Daniel, Carrie R. Sarshekeh, Amir Mehrvarz Braithwaite, Dejana Swartz, Michael D. Kopetz, Scott Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer |
title | Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer |
title_full | Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer |
title_fullStr | Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer |
title_full_unstemmed | Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer |
title_short | Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer |
title_sort | global differences in the prevalence of the cpg island methylator phenotype of colorectal cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796359/ https://www.ncbi.nlm.nih.gov/pubmed/31623592 http://dx.doi.org/10.1186/s12885-019-6144-9 |
work_keys_str_mv | AT advanishaileshmahesh globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT advanipragatishailesh globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT brownderekw globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT desantisstaciam globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT korphaisarnkrittiya globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT vonvillehelenam globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT bresslerjan globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT lopezdavids globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT davisjennifers globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT danielcarrier globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT sarshekehamirmehrvarz globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT braithwaitedejana globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT swartzmichaeld globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer AT kopetzscott globaldifferencesintheprevalenceofthecpgislandmethylatorphenotypeofcolorectalcancer |